EMEND, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: highly emetogenic cancer chemotherapy, including high-dose cisplatin (see Dosage & Administration); moderately emetogenic cancer chemotherapy (see Dosage & Administration).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
